← Compound Library

Angiotensin II

Vasoactive Peptide / Vasopressor

Also known as: ATII · Giapreza

The endogenous octapeptide vasopressor of the renin-angiotensin system. FDA approved as Giapreza for distributive shock refractory to catecholamines.

Typical Dose

20 ng/kg/min IV infusion (starting dose); titrate to hemodynamic response

Route

Intravenous infusion (ICU)

Cycle

Acute (hours to days)

Half-life

~1–2 minutes

Storage

2–8°C.

Overview

Angiotensin II is the primary effector of the renin-angiotensin system: an octapeptide produced from Angiotensin I by ACE cleavage. It acts on AT1 receptors to produce vasoconstriction, aldosterone release, sodium retention, & sympathetic activation. FDA-approved as Giapreza (2017) for septic/distributive shock unresponsive to catecholamine vasopressors.

Quick Start Guide

1

ICU use only as IV infusion under continuous hemodynamic monitoring.

Research Indications

Distributive shock (vasopressor)

Most Effective

FDA approved. ATHOS-3 trial showed improved MAP with less catecholamine use.

Side Effects & Safety

Common

  • Hypertension
  • Thrombosis
  • Tachycardia

Uncommon

  • Thrombocytopenia
  • Fungal infection

When to Stop

  • Uncontrolled hypertension
  • Signs of allergic reaction

How to Reconstitute

1

Commercial product for IV use. Dilute per package insert.

Dosing math: Clinical ICU product only.

Quality Indicators

Good — use as normal

  • Per manufacturer

Discard immediately

  • Per manufacturer

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample